Teva Pharmaceutical Industries and Lonza will establish a joint venture to develop, manufacture and market a portfolio of biosimilars. The joint venture is expected to begin activities during 1Q09, subject any applicable regulatory approvals. Financial details of this agreement were not disclosed. “We had identified biosimilars as a major growth driver for Teva in our long-term strategy and have been augmenting our knowledge base, capabilities and infrastructure to position Teva as a le...